Is There A Mortality Effect of Emipiric Colistin In The Treatment of Acinetobacter Baumanni?

To investigate the effect of empirical or culture based colistin therapy on the mortality of intensive care medicine (ICU) patients with severe sepsis and septic shock. Patients treated in three Intensive Care Units of medical faculty of Erciyes University were included in this retrospective, descriptive study. The groups did not differ regarding the mean duration of intensive care stay (15 days vs. 20 days, p = 0.20) or in terms of the intensive care mortality (58.3% vs. 72.7%, p = 0.31). There was also no difference between the groups in 30-day in hospital mortality (61.1% vs. 78.8%, p = 0.12). In patients with severe sepsis/septic shock, there were no differences between the groups in which the colistin therapy was initiated empirically or based on sensitivity test results.

PDF

___

1.Di Popolo A, Giannouli M, Triassi M, Brisse S, Zarrilli R. Molecular epidemiological investigation of multidrug‐resistant Acinetobacter baumannii strains in four Mediterranean countries with a multilocus sequence typing scheme. Clin Microbiol Infect 2011; 17: 197-201.

2. Meric M, Kasap M, Gacar G, et al. Emergence and spread of carbapenem-resistant Acinetobacter baumannii in a tertiary care hospital in Turkey. FEMS Microbiol Lett 2008; 282: 214-218.

3. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multi drug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007; 51: 3471- 3484.

4. Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect 2006; 12: 826-836.

5. Biswas S, Brunel JM, Dubus JC, ReynaudGaubert M, Rolain JM. Colistin: an update on the antibiotic of the 21st century. Expert Rev Anti Infect Ther 2012; 10: 917-934.

6. Garnacho J, Sole-Violan J, Sa-Borges M, Diaz E, Rello J. Clinical impact of pneumonia caused by Acinetobacter baumannii in intubated patients: a matched cohort study. Crit Care Med 2003; 31: 2478-2482.

7. Blot S, Vandewoude K, Colardyn F. Nosocomial bacteremia involving Acinetobacter baumannii in critically ill patients: a matched cohort study. Intensive Care Med 2003; 29: 471-475.

8. Falagas ME, Rafailidis PI. Attributable mortality of Acinetobacter baumannii: no longer a controversial issue. Crit Care 2007; 11: 134.

9. Murphy SL, Xu J, Kochanek KD. Deaths: final data for 2010. Natl Vital Stat Rep 2013; 61: 1-117.

10. Joly-Guillou ML, Wolff M, Pocidalo JJ, Walker F, Carbon C. Use of a new mouse model of Acinetobacter baumannii pneumonia to evaluate the postantibiotic effect of imipenem. Antimicrob Agents Chemother 1997; 41: 345-351.

11. Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013; 39: 165-228.

12. Michalopoulos AS, Falagas ME. Colistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patients. Ann Intensive Care 2011; 1: 30.

13. Lu Q, Girardi C, Zhang M, et al. Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa. Intensive Care Med 2010; 36(7): 1147-1155.

14. Trotman RL, Williamson JC, Shoemaker DM, Salzer WL. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis 2005; 41: 1159-1166.

15. Fishbain J, Peleg AY. Treatment of Acinetobacter infections. Clin Infect Dis 2010; 51: 79-84.

16. Nation RL, Garonzik SM, Li J, et al. Updated US and European dose recommendations for intravenous colistin: how do they perform? Clin Infect Dis 2016; 62: 552-558.

17. Pogue JM, Ortwine JK, Kaye KS. Editorial commentary: Optimal usage of colistin: are we any closer? Clin Infect Dis 2015; 61: 1778-1780.

18. Jones CL, Clancy M, Honnold C, et al. Fatal outbreak of an emerging clone of extensively drug-resistant Acinetobacter baumannii with enhanced virulence. Clin Infect Dis 2015; 61: 145- 154.

19. Martin-Loeches I, Deja M, Koulenti D, et al. Potentially resistant microorganisms in intubated patients with hospital-acquired pneumonia: the interaction of ecology, shock and risk factors. Intensive Care Med 2013; 39: 672-681.

20. Robenshtok E, Paul M, Leibovici L, et al. The significance of Acinetobacter baumanniibacteraemia compared with Klebsiella pneumoniae bacteraemia: risk factors and outcomes. J Hosp Infect 2006; 64: 282-287.

21. Abbo A, Carmeli Y, Navon-Venezia S, SiegmanIgra Y, Schwaber MJ. Impact of multi-drugresistant Acinetobacter baumannii on clinical outcomes. Eur J Clin Microbiol Infect Dis 2007; 26: 793-800.

22. Inchai J, Pothirat C, Bumroongkit C, Limsukon A, Khositsakulchai W, Liwsrisakun C. Prognostic factors associated with mortality of drug-resistant Acinetobacter baumannii ventilator-associated pneumonia. J Intensive Care 2015; 3: 9.

23. Sunenshine RH, Wright MO, Maragakis LL, et al. Multidrug-resistant Acinetobacter Infection Mortality Rate and Length of Hospitalization. Emerg Infect Dis 2007; 13: 97-103.

24. Garnacho-Montero J, Dimopoulos G, Poulakou G, et al. Task force on management and prevention of Acinetobacter baumannii infections in the ICU. Intensive Care Med 2015; 41: 2057- 2075.

25. Çakan MZ, Demirkıran H. (2018). Ventilatör ilişkili pnömoni önleme paketine uyumun arttırılmasının ventilatör ilişkili pnömoni üzerine etkisi. Uzmanlık Tezi. Van Yüzüncü Yıl Üniversitesi, Van.

26. Michalopoulos A, Fotakis D, Virtzili S, et al. Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study. Respir Med 2008; 102: 407-412